Neuropsychiatry, NorthWestern Mental Health, Melbourne Health, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia.
Department of Neurology, Evaggelismos Hospital, Athens, Greece.
J Neurol Sci. 2022 Nov 15;442:120437. doi: 10.1016/j.jns.2022.120437. Epub 2022 Sep 25.
There has not been any examination of the risk factors associated with mortality in Huntington's Disease (HD) in an Australian cohort.
This retrospective study included inpatients admitted to a specialist neuropsychiatry service in Melbourne, Australia. HD status was based on genetic testing. Risk factors included age of onset, CAG repeat length and neuroimaging. Mortality data was acquired through the Australian Institute of Health and Welfare National Death Index.
The cohort included 83 participants, with 44 (53%) deceased. The median age of death was 59 years and median survival was 18.8 years from onset age (median 41.0 years). CAG repeat length (median 44.0, IQR 42.5, 47.0) was inversely correlated with age of onset (r = -0.73) and age at death (r = -0.80) but was not correlated with mortality status. There was no difference in functional and cognitive assessments, nor brain volumes, in the alive group compared to the deceased group. There were more people who were alive who had a positive family history of a psychiatric condition (p = 0.006) or dementia (p = 0.009). Standardised mortality ratios demonstrated a 5.9× increased risk of death for those with HD compared to the general population.
This is the first study to examine risk factors of mortality in HD in an Australian cohort. Median survival in our cohort is consistent with previous studies in HD, and markedly reduced compared to the general Australian population. CAG repeat length was not associated with mortality suggesting that non-genetic factors contribute to mortality status and warrant further investigation.
在澳大利亚队列中,尚未对亨廷顿病(HD)相关的死亡风险因素进行任何检查。
本回顾性研究纳入了在澳大利亚墨尔本一家神经精神病学专科服务机构住院的患者。HD 状态基于基因检测。风险因素包括发病年龄、CAG 重复长度和神经影像学。死亡率数据通过澳大利亚卫生和福利研究所国家死亡索引获得。
该队列包括 83 名参与者,其中 44 名(53%)死亡。死亡的中位年龄为 59 岁,从发病年龄开始的中位生存时间为 18.8 年(中位 41.0 岁)。CAG 重复长度(中位数 44.0,IQR 42.5,47.0)与发病年龄(r=-0.73)和死亡年龄(r=-0.80)呈负相关,但与死亡率无关。在存活组和死亡组之间,功能和认知评估以及脑容量没有差异。有更多的存活者有精神疾病(p=0.006)或痴呆(p=0.009)家族史。标准化死亡率比值表明,与普通人群相比,HD 患者死亡的风险增加了 5.9 倍。
这是首次在澳大利亚队列中检查 HD 死亡风险因素的研究。我们队列的中位生存时间与之前的 HD 研究一致,与普通澳大利亚人群相比明显降低。CAG 重复长度与死亡率无关,这表明非遗传因素对死亡率状况有影响,值得进一步研究。